{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:04:39Z","timestamp":1733547879219,"version":"3.30.1"},"reference-count":27,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2024.2024.0199","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:49:55Z","timestamp":1723099795000},"source":"Crossref","is-referenced-by-count":0,"title":["Secondary Solid Cancers Among Patients with Philadelphia Chromosome- Negative Myeloproliferative Neoplasms: A Multicenter Study"],"prefix":"10.4274","author":[{"given":"Fehmi","family":"Hindilerden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zge Nuran","family":"Akay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynur","family":"Da\u011flar Aday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine","family":"G\u00fclt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"Nal\u00e7ac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130pek","family":"Y\u00f6nal Hindilerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","unstructured":"1. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220-2228.","journal-title":"Blood"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms","volume":"1","author":"Tefferi","year":"2015","unstructured":"2. Tefferi A, Pardanani A. Myeloproliferative neoplasms. JAMA Oncol. 2015;1:97-105.","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","unstructured":"3. Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416-1430.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","unstructured":"4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","unstructured":"5. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176-2184.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Stempel JM, Wang R, Shallis RM, Huntington SF, Zeidan AM, Neparidze N, Di M, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood. 2022;140(Suppl 1):11004-11006.","DOI":"10.1182\/blood-2022-165156"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","unstructured":"7. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, S\u00f8rensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study. Blood. 2011;118:6515-6520.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.25700","article-title":"Second cancers in MPN: survival analysis from an international study","volume":"95","author":"Marchetti","year":"2020","unstructured":"8. Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2020;95:295-301.","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","unstructured":"9. Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, Bosi A, Vannucchi AM. Risk of second cancers in chronic myeloproliferative neoplasms. Blood. 2012;119:3861-3862.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","unstructured":"10. Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Bj\u00f6rkholm M, Kristinsson SY, Hultcrantz M. Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients. Leukemia. 2018;32:2203-2210.","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long\u2010term follow\u2010up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","unstructured":"11. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long\u2010term follow\u2010up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214-220.","DOI":"10.1016\/j.leukres.2012.10.020"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ejh.12437","article-title":"Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"94","author":"Hasselbalch","year":"2015","unstructured":"13. Hasselbalch HC. Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol. 2015;94:96-98.","journal-title":"Eur J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Cumbo C, Anelli L, Zagaria A, Coccaro N, Tarantini F, Specchia G, Musto P, Albano F. Second cancer onset in myeloproliferative neoplasms: what, when, why? Int J Mol Sci. 2022;23:3177.","DOI":"10.3390\/ijms23063177"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"15. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","unstructured":"16. Khanal N, Giri S, Upadhyay S, Shostrom VK, Pathak R, Bhatt VR. Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study. Leuk Lymphoma. 2016;57:129-133.","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Brunner AM, Hobbs G, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016;57:1197-1200.","DOI":"10.3109\/10428194.2015.1071490"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1002\/cam4.5666","article-title":"Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms","volume":"12","author":"Zhang","year":"2023","unstructured":"18. Zhang Y, Han Y, Teng G, Du C, Gao S, Yuan W, Zhang L, Bai J. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms. Cancer Med. 2023;12:9236-9246.","journal-title":"Cancer Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis","volume":"94","author":"Pettersson","year":"2015","unstructured":"19. Pettersson H, Knutsen H, Holmberg E, Andr\u00e9asson B. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152-156.","journal-title":"Eur J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"A nested case-control study","volume":"33","author":"Barbui","year":"2019","unstructured":"20. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33:1996-2005.","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219-3225.","DOI":"10.1182\/blood-2011-11-394775"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-A puzzle still to be solved","volume":"23","author":"Bhuria","year":"2022","unstructured":"22. Bhuria V, Baldauf CK, Schraven B, Fischer T. Thromboinflammation in myeloproliferative neoplasms (MPN)-A puzzle still to be solved. Int J Mol Sci. 2022;23:3206.","journal-title":"Int J Mol Sci"},{"key":"ref22","unstructured":"23. Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I. Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res. 2014;34:2489-2496."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","unstructured":"24. Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023;7:734-743.","journal-title":"Blood Adv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ejh.12787","article-title":"Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Hansen","year":"2017","unstructured":"25. Hansen IO, S\u00f8rensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2017;98:75-84.","journal-title":"Eur J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219-3225.","DOI":"10.1182\/blood-2011-11-394775"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/bloodadvances.2019000655","article-title":"Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms","volume":"3","author":"Hong","year":"2019","unstructured":"27. Hong J, Lee JH, Byun JM, Lee JY, Koh Y, Shin DY, Lee JO, Hwang SM, Choi HS, Kim I, Yoon SS, Bang SM. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv. 2019;3:3700-3708.","journal-title":"Blood Adv"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:52:03Z","timestamp":1733467923000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-63549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":27,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0199","relation":{},"ISSN":["1300-7777"],"issn-type":[{"type":"print","value":"1300-7777"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}